EMA Considers How To Verify Potency Of Next-Generation COVID-19 Vaccines

 
• By Vibha Sharma

Companies approaching the European Medicines Agency with their development plans for new COVID-19 vaccines are being asked to consider immunobridging studies if placebo-controlled trials are not feasible.

Covid variant
Development of second-generation COVID-19 vaccines poses new challenges • Source: Alamy

More from Vaccines

More from Pink Sheet